Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 27, Pages 10966-10971Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1208698109
Keywords
cancer immunotherapy; Fc engineering; human FCGR2B; antibody-dependent cell-mediated cytotoxicity
Categories
Funding
- National Institutes of Health
- Paralyzed Veterans of America Research Foundation [2757]
Ask authors/readers for more resources
By virtue of their ability to induce apoptosis and regulate growth, differentiation, and cytokine responses, the tumor necrosis factor receptor (TNFR) superfamily members have emerged as attractive targets for anticancer therapeutics. Agonistic antibodies to apoptosis-inducing TNFRs, such as death receptor 5 (DR5), although displaying impressive activities against a variety of tumors in preclinical models, appear to be less active in clinical trials. We report that the in vivo apoptotic and antitumor activities of these antibodies have an absolute requirement for the coengagement of an inhibitory Fc gamma receptor, Fc gamma RIIB. Anti-DR5 antibodies of the type currently in clinical trials have weak Fc gamma RIIB binding and thus are compromised in their proapoptotic and antitumor activities in both colon and breast carcinoma models. Enhancing Fc gamma RIIB engagement increases apoptotic and antitumor potency. Our results demonstrate that Fc domain interactions are critical to the therapeutic activity of anti-DR5 antibodies and, together with previous reports on agonistic anti-CD40 antibodies, establish a common requirement for Fc gamma RIIB coengagement for optimal biological effects of agonistic anti-TNFR antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available